Pharmaceuticals, Biotechnology and Life Sciences
Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb Co but the Swiss drugmaker’s treatment is making up lost ground.
Everyone gets an itch once in a while. Usually it only lasts for a short time and is often caused by annoyances like a mosquito bite or scratchy fabric. However, if an itch lasts for more than six weeks, say dermatologists from the American Academy of Dermatology, it is considered a chronic itch and is more likely to disrupt your life.
The fourth quarter was a continuation of the strong performance and business momentum AbbVie has delivered since becoming an independent company in 2013.
Theradiag and its South Korean partners, Professor Chang-sik Yu and his team at Asan Medical Center and CbsBioscience will receive €1.3 million financial support from Eurostars program for its Pioneer collaborative project undertaken by its Prestizia molecular biology platform.
French drugmaker focused on diabetes treatments Poxel, said it expectedly did not generate meaningful revenues in the fourth quarter of 2016, but it is on track for developing two of its programs.
The Vetoquinol Group has reported sales of €350.3 million for 2016, representing like-for-like growth of 4.3%.
Beximco Pharmaceuticals has posted earnings of $1,113,722, for the second half of 2016, compared to $944,662 to the same period last year.
Stallergenes Greer, a biopharmaceutical company specializing in treatments for respiratory allergies, has reported positive topline results for a phase 3 clinical…
FDA found that certain teething tablets for children sometimes exceed the amount of belladonna – a toxic substance – and has asked the company that makes them to recall such medicine.
Bristol-Myers Squib on Thursday posted fourth quarter net earnings of $1.1 billion, driven ly by increased sales of Opdivo and Eliquis.